Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.42 |
| ▸ | CCND1 | P24385 | 3/20 | 0.42 |
| ▸ | BCL2 | P10415 | 4/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.41 |
| ▸ | BID | P55957 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19419611 | 0.94 | BCL2 (0.41) | EGFRCDK4CCND1BCL2MCL1 | |
| SCHEMBL22686504 | 0.86 | ALB (0.42) | EGFRCDK4CCND1BCL2MCL1 | |
| SCHEMBL22700473 | 0.86 | AKR1B1 (0.36) | EGFRCDK4CCND1BCL2MCL1 | |
| SCHEMBL19038888 | 0.80 | BCL2 (0.43) | EGFRCDK4CCND1BCL2MCL1 | |
| SCHEMBL22700390 | 0.78 | MCL1 (0.50) | BCL2MCL1MEN1MAPTKMT2A | |
| SCHEMBL22700400 | 0.78 | MAPT (0.36) | BCL2MCL1MEN1MAPTKMT2A | |
| SCHEMBL22700489 | 0.77 | BCL2 (0.40) | BCL2MCL1MEN1KMT2AHSD17B10 | |
| SCHEMBL1890942 | 0.77 | BCL2 (0.37) | EGFRCDK4CCND1BCL2MCL1 | |
| SCHEMBL22700774 | 0.77 | CNR2 (0.34) | MAPTALDH1A1ALOX15MAPK1HSD17B10 | |
| SCHEMBL22700765 | 0.77 | SMN1; SMN2 (0.32) | KMT2AALDH1A1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | Nearmedic International Limited (CY) | 2020-11-26 | — | — | US | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20150313906-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-20150313906-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | disclosed |
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1824467-A4 | APOGOSSYPOLONE AND THE USES THEREOF | UNIV MICHIGAN (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1824467-A2 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060178435-A1 | Apogossypolone and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006050447-A2 | APOGOSSYPOLONE AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | EGFR 3068/4885CDK4 88/4885CCND1 155/4885 |
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | DNM2, DNM1, MAVS | EGFR 4699/4885CDK4 331/4885CCND1 200/4885 |
| US-20060178435-A1 | Apogossypolone and the uses thereof | BCL2, BAD, BAX | EGFR 1727/4885CDK4 281/4885CCND1 141/4885 |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | CYP17A1, HSD17B7, CYP27A1 | EGFR 2765/4885CDK4 1904/4885CCND1 1659/4885 |
| US-20090118377-A1 | APOGOSSYPOLONE AND THE USES THEREOF | BCL2, BAD, BAX | EGFR 1727/4885CDK4 281/4885CCND1 141/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | EGFR 1846/4885CDK4 21/4885CCND1 96/4885 |
| US-20150313906-A1 | COMBINATION | EZH2, BMI1, DOT1L | EGFR 1087/4885CDK4 185/4885CCND1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.